Micro
Emerging
Active
SYNH stock up 72% on $8M sale, reduced stake by Kynam Capital
New narrative with limited coverage — still forming.
Score
0.2
Velocity
▲ 0.0
Articles
4
Sources
1
Sentiment Timeline
Sector Performance
Stock Performance
Event Timeline
Related Articles
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
Nasdaq
·
Mar 22, 2026
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a …
Nasdaq
·
Mar 22, 2026
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems …
Nasdaq
·
Mar 21, 2026
🤖
AI Overview
What happened: SYNH stock surged 72% after Kynam Capital sold a $8M stake, reducing their position by 469,041 shares. Meanwhile, LEG stock rose 13% following a $2.5B acquisition deal with Somnigroup International. RTW Investments bought 4,124,755 shares of Cogent Biosciences, increasing their stake to 7,592,255 shares, worth $219.88M.
Market impact: The biotech sector saw mixed activity. SYNH's price increase could indicate bullish sentiment, while Kynam's sale might signal profit-taking. LEG's acquisition boosts the furniture and bedding sector. RTW's significant buy into Cogent Biosciences suggests confidence in their upcoming drug launch.
What to watch next: SYNH's earnings report on March 15 will provide insight into their financial health. LEG's acquisition completion, expected in Q2 2023, will determine if the deal goes through as planned. Cogent Biosciences' upcoming drug launch, with a PDUFA date set for August 2023, will reveal if RTW's bullish stance is justified.
Market impact: The biotech sector saw mixed activity. SYNH's price increase could indicate bullish sentiment, while Kynam's sale might signal profit-taking. LEG's acquisition boosts the furniture and bedding sector. RTW's significant buy into Cogent Biosciences suggests confidence in their upcoming drug launch.
What to watch next: SYNH's earnings report on March 15 will provide insight into their financial health. LEG's acquisition completion, expected in Q2 2023, will determine if the deal goes through as planned. Cogent Biosciences' upcoming drug launch, with a PDUFA date set for August 2023, will reveal if RTW's bullish stance is justified.
AI Overview as of Apr 13, 2026
Timeline
First SeenMar 21, 2026
Last UpdatedMar 21, 2026